AMP Workshop — Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study

Wednesday, November 12, 12:00pm - 12:50pm (EST)

The emergence of NGS-based MRD technologies offers a significant advantage over existing approaches in hemato-oncology, simultaneously providing lower detection limits and deeper genomic insights.

Hear from Dr. Sean Glenn, Roswell Park Cancer Institute, as he shares his insights using the SureSeq™ Myeloid MRD Panel* in a retrospective cohort study of research specimens collected from patients undergoing AML treatment.

Attendees will learn about the ability of the SureSeq Myeloid MRD Panel to assess residual disease signals as compared to other existing technologies in the field and how targeted NGS-based panels, combined with optimized bioinformatic analysis, can enhance our understanding of AML MRD.

*Research Use Only; Not for Use in Diagnostic Procedures

Time shown in-04:00America, New York

Link:

Wednesday, November 12, 12:00pm - 12:50pm (EST)

Please fill out the information below to register for the event.

Goingdone
Interestedstar_border
Not goingclear

RSVP'ing to this event will not guarantee you a seat, but will allow you to receive tailored event reminders and a notification when the event recording will be available

Name

Work Email

Confirmed

We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.

Add to Calendar2025/11/12 12:00:002025/11/12 12:50:00America/New_YorkAMP Workshop — Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort studyThe emergence of NGS-based MRD technologies offers a significant advantage over existing approaches in hemato-oncology, simultaneously providing lower detection limits and deeper genomic insights.

Hear from Dr. Sean Glenn, Roswell Park Cancer Institute, as he shares his insights using the SureSeq™ Myeloid MRD Panel* in a retrospective cohort study of research specimens collected from patients undergoing AML treatment.

Attendees will learn about the ability of the SureSeq Myeloid MRD Panel to assess residual disease signals as compared to other existing technologies in the field and how targeted NGS-based panels, combined with optimized bioinformatic analysis, can enhance our understanding of AML MRD.

*Research Use Only; Not for Use in Diagnostic ProceduresBoston, MA, USAOGTcontact@ogt.comfalse30

Confirmed

We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.

Thank you!

Your changes have been saved. Thanks for keeping us updated.

Boston, MA, USA

OGT, contact@ogt.com